OnKure Therapeutics Inc. (OKUR)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
OnKure Therapeutics Spotlights Allosteric PI3Kα Drugs as 2027 IND Targets Near
OnKure Therapeutics NASDAQ: OKUR used a scientific webcast to outline its strategy for developing mutant-selective PI3Kα inhibitors, emphasizing allosteric inhibition as a potential way to improve efficacy and tolerability in cancer and vascular anomalies.
OnKure: Looking To Alter PI3K Inhibitor Targeting In Breast Cancer And Beyond
Initial OnKure Therapeutics, Inc. data from the phase 1 PIKture-01 study, using OKI-219 for the treatment of patients with PI3Ka-H1047R breast cancer and solid tumors, is expected in Q4 of 2024. OKI-219 has 80X fold improved selectivity PI3K-a targeting versus wild-type PI3K-a, potentially allowing for higher dosing and reducing unwanted off-target effects. The merger with Reneo Pharmaceuticals and $65 million private placement boosts OnKure's cash to $139 million, funding operations into Q4 2026.
OnKure Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| IM Ilko Menkov Vestal Point Capita LLP | 1.84M | $10.45M | $7.69M | -$2.76M | -26.4% |
 James B. Tananbaum Foresite Capital Management VI LLC | 1.45M | $5.99M | $5.96M | -$20,675.13 | -0.35% |
| AH Anders Hove Acorn Capital Advisors LLC | 2.84M | $8.02M | $11.5M | $3.48M | 43.33% |
OnKure Therapeutics Inc. (OKUR) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has OnKure Therapeutics Inc. ever had a stock split?
OnKure Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Nicholas A. Saccomano CEO | NASDAQ (NMS) Exchange | 68277Q105 CUSIP |
| US Country | 45 Employees | - Last Dividend | 7 Oct 2024 Last Split | - IPO Date |
Overview
OnKure, Inc. is a biopharmaceutical company devoted to innovating and developing oncology-precision medicines aimed at the effective treatment of cancer. With a clear focus on pioneering selective inhibitors of histone deacetylases, OnKure is at the forefront of targeted cancer therapy. Since its incorporation in 2011, the company has established its headquarters in Boulder, Colorado, positioning itself as a key player in the field of cancer research and drug development.
Products and Services
OKI-179: As the flagship product in OnKure's portfolio, OKI-179 is a carefully engineered inhibitor designed for the treatment of both hematological malignancies and solid tumors. This drug represents OnKure’s commitment to advancing cancer treatment through selective targeting and inhibition of key molecular pathways involved in tumor growth and survival.
